...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: New SEDAR page

So SEDAR has finally upgraded from its 1990's era website. The new website has a handy link to show if the issuer is in default in any jurisdiction.

Zenith is shown in default of securities requirements in BC, NS, and ON. Looks like they forgot to file some documents and pay some fees.

Codes:

BC:

  • 3: The reporting issuer has failed to pay a fee required by securities laws.

NS:

  • 1: The reporting issuer has failed to file the following continuous disclosure prescribed by securities
    laws:
    • 1(b): interim financial statements;
    • 1(c): annual or interim management’s discussion and analysis (MD&A) or annual or interim
      management report of fund performance (MRFP);
    • 1(e): certification of annual or interim filings under Multilateral Instrument 52-109 Certification of
      Disclosure in Issuers’ Annual and Interim Filings (MI 52-109)
  • 3: The reporting issuer has failed to pay a fee required by securities laws.

ON:

  • 3: The reporting issuer has failed to pay a fee required by securities laws.
Share
New Message
Please login to post a reply